CN103547283A - 前列腺相关抗原分子来源的人类白细胞抗原结合肽及其使用方法 - Google Patents

前列腺相关抗原分子来源的人类白细胞抗原结合肽及其使用方法 Download PDF

Info

Publication number
CN103547283A
CN103547283A CN201180059274.2A CN201180059274A CN103547283A CN 103547283 A CN103547283 A CN 103547283A CN 201180059274 A CN201180059274 A CN 201180059274A CN 103547283 A CN103547283 A CN 103547283A
Authority
CN
China
Prior art keywords
peptide
hla
sequence numbering
cell
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201180059274.2A
Other languages
English (en)
Chinese (zh)
Inventor
托尼·怀申克
彼得·莱维卓尔斯奇
汉斯—宙戈·冉曼思
斯蒂芬·斯蒂万诺维奇
赛瑟利·戈泰芬奇斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immatics Biotechnologies GmbH
Original Assignee
Immatics Biotechnologies GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2010/069675 external-priority patent/WO2011073215A2/fr
Application filed by Immatics Biotechnologies GmbH filed Critical Immatics Biotechnologies GmbH
Publication of CN103547283A publication Critical patent/CN103547283A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464493—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • A61K39/464495—Prostate specific membrane antigen [PSMA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201180059274.2A 2010-12-14 2011-11-14 前列腺相关抗原分子来源的人类白细胞抗原结合肽及其使用方法 Pending CN103547283A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2010/069675 WO2011073215A2 (fr) 2009-12-14 2010-12-14 Peptides se liant aux hla, dérivés de molécules antigéniques associées à la prostate, et leurs procédés d'utilisation
EPPCT/EP2010/069675 2010-12-14
PCT/EP2011/070024 WO2012079878A2 (fr) 2010-12-14 2011-11-14 Peptides se liant au hla dérivés de molécules antigéniques associées à la prostate et procédés d'utilisation associés

Publications (1)

Publication Number Publication Date
CN103547283A true CN103547283A (zh) 2014-01-29

Family

ID=44983532

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180059274.2A Pending CN103547283A (zh) 2010-12-14 2011-11-14 前列腺相关抗原分子来源的人类白细胞抗原结合肽及其使用方法

Country Status (9)

Country Link
JP (1) JP6032853B2 (fr)
KR (1) KR20130126671A (fr)
CN (1) CN103547283A (fr)
AU (1) AU2011344652B2 (fr)
CA (1) CA2821582A1 (fr)
MX (1) MX2013006758A (fr)
NZ (1) NZ609916A (fr)
SG (1) SG191154A1 (fr)
WO (1) WO2012079878A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107849107A (zh) * 2015-08-05 2018-03-27 伊玛提克斯生物技术有限公司 用于前列腺癌和其他癌症免疫治疗的新型肽和肽组合物
CN108713024A (zh) * 2016-02-19 2018-10-26 伊玛提克斯生物技术有限公司 用于nhl和其他癌症免疫治疗的新型肽和肽组合物

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102013012432A1 (de) * 2013-07-29 2015-01-29 Eberhard Karls Universität Tübingen Medizinische Fakultät Immuntherapie von Prostatakrebs
CN106456784A (zh) * 2014-04-16 2017-02-22 拜康有限公司 包含摩尔过量的山梨醇的稳定蛋白质制剂
CA3172801A1 (fr) * 2015-06-12 2016-12-15 Lentigen Technology, Inc. Procede de traitement de cancer a l'aide de lymphocytes t genetiquement modifies
GB201521746D0 (en) * 2015-12-10 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
KR102639592B1 (ko) 2016-12-08 2024-02-21 이매틱스 바이오테크놀로지스 게엠베하 짝짓기가 향상된 t 세포 수용체
CA3053133A1 (fr) * 2017-02-12 2018-08-16 Neon Therapeutics, Inc. Methodes et compositions reposant sur le hla et leurs utilisations
KR102215578B1 (ko) * 2019-03-28 2021-02-15 한국과학기술연구원 인간 백혈구 항원에 특이적으로 결합하는 펩타이드 및 이의 용도

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001045728A2 (fr) * 1999-12-21 2001-06-28 Epimmune Inc. Induction de reponses immunitaires cellulaires aux antigenes du cancer de la prostate au moyen de compositions de peptides et d'acides nucleiques
WO2001075067A2 (fr) * 2000-03-31 2001-10-11 Hyseq, Inc. Nouveaux acides nucleiques et polypeptides
WO2003070889A2 (fr) * 2002-02-19 2003-08-28 Idec Pharmaceuticals Corporation Genes specifiques de la prostate et leur utilisation dans la conception ou la therapie
WO2004053075A2 (fr) * 2002-12-05 2004-06-24 Diadexus, Inc. Compositions, variants d'epissage et procedes relatifs a des genes et des proteines specifiques du sein

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA725596A (en) 1960-08-26 1966-01-11 J. Wretlind Arvid Method of preparing intravenously injectable fat emulsions free from side reactions or complications
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US20020081680A1 (en) * 2000-04-17 2002-06-27 Jiangchun Xu Compositions and methods for the therapy and diagnosis of prostate cancer
US7892559B2 (en) 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
AU2003256912A1 (en) * 2002-08-16 2004-03-03 Yeda Research And Development Co. Ltd. Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines
WO2005033265A2 (fr) * 2003-04-25 2005-04-14 Epimmune Inc. Constructions multi-epitope optimisees et leurs utilisations
WO2006023598A2 (fr) * 2004-08-19 2006-03-02 University Of Maryland, Baltimore Peptides restreints par mhc classe ii derives d'antigenes specifiques a la prostate et leur utilisation dans des vaccins destines a traiter ou a prevenir le cancer de la prostate
DE602004019215D1 (de) 2004-10-02 2009-03-12 Immatics Biotechnologies Gmbh Immunogene T-Helfer Epitope von menschlichen Tumorantigenen und deren Verwendung in immunotherapeutischen Methoden
DK1806359T3 (da) 2005-09-05 2010-06-14 Immatics Biotechnologies Gmbh Tumorassocierede peptider, der bindes promiskuøst til Humant Leukocyt-Antigen (HLA) klasse II molekyler
ATE462442T1 (de) * 2008-04-30 2010-04-15 Immatics Biotechnologies Gmbh Neuartige formulierungen von tumor-assoziierten peptiden, welche an menschliche leukozytenantigene der klasse i oder ii für impfungen binden
NO2119726T3 (fr) * 2008-05-14 2015-05-23
EP2172211B1 (fr) * 2008-10-01 2014-12-03 Immatics Biotechnologies GmbH Composition de peptide associé aux tumeurs et vaccin anti-cancer associé pour le traitement de glioblastome (GBM) et autres cancers

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001045728A2 (fr) * 1999-12-21 2001-06-28 Epimmune Inc. Induction de reponses immunitaires cellulaires aux antigenes du cancer de la prostate au moyen de compositions de peptides et d'acides nucleiques
WO2001075067A2 (fr) * 2000-03-31 2001-10-11 Hyseq, Inc. Nouveaux acides nucleiques et polypeptides
WO2003070889A2 (fr) * 2002-02-19 2003-08-28 Idec Pharmaceuticals Corporation Genes specifiques de la prostate et leur utilisation dans la conception ou la therapie
WO2004053075A2 (fr) * 2002-12-05 2004-06-24 Diadexus, Inc. Compositions, variants d'epissage et procedes relatifs a des genes et des proteines specifiques du sein

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
QIN H ET AL.: "Specific antitumor immune response induced by a novel DNA vaccine composed of multiple CTL and T helper cell epitopes of prostate cancer associated antigens", 《IMMUNOLOGY LETTERS》 *
STRUBIN,M.,ET AL: "The complete sequence of the mRNA for the HLA-DR-associated invariant chain reveals a polypeptide with an unusual transmembrane polarity", 《EMBO J.》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107849107A (zh) * 2015-08-05 2018-03-27 伊玛提克斯生物技术有限公司 用于前列腺癌和其他癌症免疫治疗的新型肽和肽组合物
US11058754B2 (en) 2015-08-05 2021-07-13 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
CN108713024A (zh) * 2016-02-19 2018-10-26 伊玛提克斯生物技术有限公司 用于nhl和其他癌症免疫治疗的新型肽和肽组合物

Also Published As

Publication number Publication date
SG191154A1 (en) 2013-07-31
WO2012079878A3 (fr) 2012-08-09
MX2013006758A (es) 2013-08-01
AU2011344652A1 (en) 2013-05-23
WO2012079878A2 (fr) 2012-06-21
KR20130126671A (ko) 2013-11-20
JP6032853B2 (ja) 2016-11-30
NZ609916A (en) 2015-03-27
JP2014502961A (ja) 2014-02-06
CA2821582A1 (fr) 2012-06-21
AU2011344652B2 (en) 2015-11-19

Similar Documents

Publication Publication Date Title
AU2020281108B2 (en) Novel peptides and combination of peptides for use in immunotherapy against cll and other cancers
CN102892777B (zh) 用于治疗胃癌和其他癌症的抗肿瘤相关肽及相关抗癌疫苗组合物
CN101765434B (zh) 抗肿瘤相关肽及相关抗癌疫苗组合物
CN103547283A (zh) 前列腺相关抗原分子来源的人类白细胞抗原结合肽及其使用方法
US10875892B2 (en) Immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL)
EP3157549B1 (fr) Nouvelle immunothérapie dirigée contre plusieurs tumeurs du sang, en particulier la leucémie lymphoïde chronique (llc)
KR101509284B1 (ko) 서바이빈으로부터 유래된 신규하고 강력한 ｍｈｃ-클래스 ｉｉ 펩티드
AU2020200066A1 (en) Novel immunotherapy against several tumors of the blood, such as acute myeloid leukemia (aml)
US9023802B2 (en) HLA-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
US9023804B2 (en) HLA-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
US10898562B1 (en) Immunotherapy against several tumors of the blood, such as acute myeloid leukemia (AML)
US20150291660A1 (en) Novel melanoma antigen peptide and uses thereof
Class et al. Patent application title: COMPOSITION OF TUMOR-ASSOCIATED PEPTIDES AND RELATED ANTI-CANCER VACCINE FOR THE TREATMENT OF GASTRIC CANCER AND OTHER CANCERS Inventors: Jens Fritsche (Tuebingen, DE) Jens Fritsche (Tuebingen, DE) Toni Weinschenk (Aichwald, DE) Steffen Walter (Reutlingen, DE) Steffen Walter (Reutlingen, DE) Peter Lewandrowski (Tuebingen-Hirschau, DE) Peter Lewandrowski (Tuebingen-Hirschau, DE) Harpeet Singh (Tuebingen, DE) Assignees: IMMATICS BIOTECHNOLOGIES GMBH
STICKEL et al. Sommaire du brevet 2946349
EP2651434A2 (fr) Peptides se liant au hla dérivés de molécules antigéniques associées à la prostate et procédés d'utilisation associés

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned
AD01 Patent right deemed abandoned

Effective date of abandoning: 20180209